2007–2016 (n=75) | 2017–2021 (n=204) | P value | |
Age, years, mean±SD | 63.2±12.14 | 60.80±14.90 | 0.216 |
FIGO stage at diagnosis, n (%) | 0.435 | ||
III | 57 (76.0%) | 144 (70.6%) | |
IV | 18 (24.0%) | 58 (28.4%) | |
Missing | 0 (0.0%) | 2 (1.0%) | |
Neoadjuvant chemotherapy, n (%) | <0.001* | ||
Yes | 67 (89.3%) | 111 (54.4%) | |
No | 8 (10.7%) | 93 (45.6%) | |
Missing | |||
Residual disease, n (%) | 0.023* | ||
Yes | 14 (18.7%) | 18 (8.8%) | |
No | 61 (81.3%) | 185 (90.7%) | |
Missing | 0 (0.0%) | 1 (0.5%) | |
BRCA mutation, n (%) | 0.842 | ||
No mutation | 24 (32.0%) | 53 (26.0%) | |
BRCA 1 or BRCA 2 mutation | 8 (10.7%) | 16 (7.8%) | |
Missing | 43 (57.3%) | 135 (66.2%) | |
Initial CA125, median (P25–P75) | <0.001* | ||
Initial CA125 (IU/L) | 1283 (257–2424) | 336 (96–861) | |
Histological type, n (%) | <0001* | ||
Serous/serous papillary | 50 (74.6%) | 167 (85.6%) | |
Mucinous | 0 (0.0%) | 5 (2.6%) | |
Endometrioid | 6 (8.9%) | 5 (2.6%) | |
Clear cells | 1 (1.5%) | 1 (0.5%) | |
Undifferentiated | 10 (14.9%) | 2 (1.0%) | |
Other | 0 (0.0%) | 15 (7.7%) | |
Missing | 8 (10.7%) | 9 (4.4%) | |
Grade, n (%) | 0.571 | ||
Low grade (I–II) | 7 (9.3%) | 24 (11.8%) | |
High grade (III) | 60 (80.0%) | 159 (77.9%) | |
Missing | 8 (10.7%) | 21 (10.3%) | |
Ascites, n (%) | 0.267 | ||
Yes | 49 (65.3%) | 122 (59.8%) | |
No | 8 (10.7%) | 32 (15.7%) | |
Missing | 18 (24.0%) | 50 (24.5%) | |
Ascites volume, n (%) | <0.001* | ||
No ascite | 8 (10.7%) | 32 (15.7%) | |
0–500 mL | 14 (18.7%) | 72 (35.3%) | |
500 mL–1 L | 3 (4.0%) | 13 (6.4%) | |
1–3 L | 18 (24.0%) | 13 (6.4%) | |
>3 L | 14 (18.7%) | 24 (11.8%) | |
Missing | 18 (24.0%) | 50 (24.5%) | |
Maintenance therapy, n (%) | 0.011* | ||
Yes | 7 (9.3%) | 47 (23.0%) | |
No | 67 (89.3%) | 157 (77.0%) | |
Missing | 1 (1.3%) | 0 (0.0%) | |
Maintenance therapy drug (patients with maintenance therapy: n=54) | <0.001* | ||
PARPi | 0 (0.0%) | 43 (91.5%) | |
Bevacizumab | 7 (100.0%) | 4 (8.5%) |
*Statistically significant.
BRCA, breast cancer gene; CA125, cancer antigen 125; FIGO, International Federation of Gynecology and Obstetrics; PARPi, poly(ADP-ribose) polymerase inhibitor.